Clinical Trial Update: Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and preliminary efficacy of RAD001 (everolimus) in Chinese patients with advanced pulmonary neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• RAD001 (Everolimus) (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lung Neuroendocrine Neoplasm | Phase 1 | Status: COMPLETED